Clinical Trials Drug Efficacy Drug Development Drug Trials Efficacy Studies Psychedelic Research Randomized Controlled Trials Pharmacovigilance Pharmacology Evidence-Based Medicine Systematic Reviews Drug Studies Epidemiology Medical Studies Neuroscience Pilot Studies Trial Applications Psychiatric Interventions Implant Studies Validation Studies Trial Results Psychedelic Studies Trial Design COVID-19 Impact Randomized Trials AI Applications Study Findings Women's Health Initiative Psychological Therapies Medical Curriculum Phase 2 Trials Ophthalmology Medical Research Cancer Therapy Development Therapeutic Benefits of MDMA Weight Loss Studies Drug Safety Real-World Evidence Drug Formulations Study Design Real-World Data Pediatric Studies Phase Trials Pharmacokinetics Study Trials Trials Data Analysis Psychiatric Studies Quantitative Studies
The decision follows Phase 3 MajesTEC-3 results that showed an 83% lower risk of progression or death versus daratumumab-based regimens.
